Challenges and opportunities in the manufacture and expansion of cells for therapy

References

• Thomas D. Stem cell production: overcoming the technical and commercial challenges. Innovations Pharm Technol. 2012;43:66–70.
   Google Scholar
• Paull D, Sevilla A, Zhou H, et al. Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells [Report]. Nat Methods. 2015;12:885+.
   PubMed Web of Science ®Google Scholar
• Rowley JA. Developing cell therapy biomanufacturing processes. Chem Eng Prog. 2010;106(11):50–55.
   Web of Science ®Google Scholar
• Hümmer C, Poppe C, Bunos M, et al. Automation of cellular therapy product manufacturing: results of a split validation comparing CD34 selection of peripheral blood stem cell apheresis product with a semi-manual vs. an automatic procedure. J Transl Med. 2016;14(1):76.
   PubMed Web of Science ®Google Scholar
• Lysaght MJ, Hazlehurst AL. Tissue engineering: the end of the beginning. Tissue Eng. 2004;10(1–2):309–320. PubMed PMID: 215615170. DOI:10.1089/107632704322791943
   PubMedGoogle Scholar
• Simaria AS, Hassan S, Varadaraju H, et al. Allogeneic cell therapy bioprocess economics and optimization: single‐use cell expansion technologies. Biotechnol Bioeng. 2014;111(1):69–83.
   PubMed Web of Science ®Google Scholar
• Thirumala S, Goebel WS, Woods EJ. Manufacturing and banking of mesenchymal stem cells. Expert Opin Biol Ther. 2013;13(5):673–691.
   PubMed Web of Science ®Google Scholar
• Zweigerdt R. Large scale production of stem cells and their derivatives. Engineering of Stem Cells. Springer; 2009. p. 201–235.
   Google Scholar
• Martin I, Simmons PJ, Williams DF. Manufacturing challenges in regenerative medicine. Sci Transl Med. 2014;6(232):232fs16–232fs16.
   PubMed Web of Science ®Google Scholar
• Vaes B, Craeye D, Pinxteren J. Quality control during manufacture of a stem cell therapeutic. BioProcess Int Suppl Cell Ther Anal. 2012;10:50–55.
   Google Scholar
• He B, Baird R, Butera R, et al. Grand challenges in interfacing engineering with life sciences and medicine. IEEE Trans Biomed Eng. 2013;60(3):589–598.
   PubMed Web of Science ®Google Scholar
• Hanley PJ, Mei Z, Durett AG, et al. Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System. Cytotherapy. 2014;16(8):1048–1058.
   PubMed Web of Science ®Google Scholar
• Kempf H, Andree B, Zweigerdt R. Large-scale production of human pluripotent stem cell derived cardiomyocytes. Adv Drug Deliv Rev. 2016;96:18–30.
   PubMed Web of Science ®Google Scholar
• Prestwich GD, Erickson IE, Zarembinski TI, et al. The translational imperative: making cell therapy simple and effective. Acta Biomater. 2012;8(12):4200–4207.
   PubMed Web of Science ®Google Scholar
• Mack CA. Fifty s. IEEE Trans Semicond Manuf. 2011;24(2):202–207.
   Web of Science ®Google Scholar
• Noyce RN, Hoff ME. A history of microprocessor development at Intel. IEEE Micro. 1981;1(1):8–21.
   Google Scholar
• Bowden MJ. Moore’s Law and the technology S-curve. Stevens Alliance Technol Manag. 2004;8(1):1–4.
   Google Scholar
• van den Ende J, Kemp R. Technological transformations in history: how the computer regime grew out of existing computing regimes. Res Policy. 1999 11;28(8):833–851. DOI:10.1016/S0048-7333(99)00027-X
   Web of Science ®Google Scholar
• Yelle LE. The learning curve: historical review and comprehensive survey. Decis Sci. 1979;10(2):302–328.
   Google Scholar
• Mehta SS. Commercializing successful biomedical technologies: basic principles for the development of drugs, diagnostics and devices. Cambridge: Cambridge University Press; 2008. ( (Book, Whole)).
   Google Scholar
• Mason C, Dunnill P. A brief definition of regenerative medicine. Regen Med. 2008;3: 1–5. 2008/01//:1+.
   PubMed Web of Science ®Google Scholar
• Mason C, Manzotti E. Regenerative medicine cell therapies: numbers of units manufactured and patients treated between 1988 and 2010. Regen Med. 2010 May;5(3):307–313. doi: 10.2217/rme.10.37.
   PubMed Web of Science ®Google Scholar
• Bresler H, Kramer D. Preparing for commercial-scale manufacturing and delivery of cell-based products: charting a course for success. Cell Gene Ther. 2004;1(May 2004):23–32. English.
   Google Scholar
• Lysaght MJ, Jaklenec A, Deweerd E. Great expectations: private sector activity in tissue engineering, regenerative medicine, and stem cell therapeutics. Tissue Eng. 2008;14(2):305–315.
   Google Scholar
• Davie NL, Brindley DA, Culme-Seymour EJ, et al. Streamlining cell therapy manufacture. BioProcess Int. 2012;10(3):24–27.
   Google Scholar
• Mason C, Brindley DA, Culme-Seymour EJ, et al. Cell therapy industry: billion dollar global business with unlimited potential. Regen Med. 2011 May;6(3):265–272. doi: 10.2217/rme.11.28.
   PubMed Web of Science ®Google Scholar
• Culme-Seymour EJ, Davie NL, Brindley DA, et al. A decade of cell therapy clinical trials (2000-2010). Regen Med 2012;455+. 2012/07//.
   Google Scholar
• Mason C, Manzotti E. Regen: the industry responsible for cell-based therapies. Regen Med. 2009;4(6):783–785. 2009/11/01. DOI:10.2217/rme.09.72
   PubMed Web of Science ®Google Scholar
• Sharp P, Cooney C, Kastner M, et al. The third revolution: the convergence of the life sciences, physical sciences, and engineering. Massachusetts Institute of Technology; 2011.
   Google Scholar
• Heathman TR, Nienow AW, McCall MJ, et al. The translation of cell-based therapies: clinical landscape and manufacturing challenges. Regen Med. 2015;10(1):49–64.
   PubMed Web of Science ®Google Scholar
• Alliance for Regenerative Medicine 2017 [cited]; The Alliance for Regenerative Medicine (ARM) is the preeminent global advocate for regenerative and advanced therapies. ARM fosters research, development, investment and commercialization of transformational treatments and cures for patients worldwide.]. Available from: https://alliancerm.org/page/clinical-trials-products
   Google Scholar
• ClinicalTrials.gov: National Library of Medicine (US). 2017 [cited]; ClinicalTrials.gov contains information about medical studies in human volunteers. Studies listed in the database are conducted in all 50 States and in 200 countries.; ClinicalTrials.gov is a Web-based resource that provides patients, their family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions.]. Available from: https://clinicaltrials.gov/
   Google Scholar
• Hourd P, Chandra A, Medcalf N, et al. Regulatory challenges for the manufacture and scale-out of autologous cell therapies. In: StemBook (Internet). MA, USA: Harvard Stem Cell Institute. 2014.
   Google Scholar
• Abbasalizadeh S, Baharvand H. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies. Biotechnol Adv. 2013;31(8):1600–1623.
   PubMed Web of Science ®Google Scholar
• Shyam H, Singh SK, Kant R, et al. Mesenchymal stem cells in regenerative medicine: a new paradigm for degenerative bone diseases. Regen Med. 2017;12(2):111–114. 2017/03/01. DOI:10.2217/rme-2016-0162
   PubMed Web of Science ®Google Scholar
• Martin PA, Coveney C, Kraft A, et al. Commercial development of stem cell technology: lessons from the past, strategies for the future. Regen Med. 2006 Nov 1;1(6):801–807. PubMed PMID: 17465761. DOI:10.2217/17460751.1.6.801
   PubMed Web of Science ®Google Scholar
• Cmglee. Comparison of semiconductor process nodes: Wikimedia Commons; 2017 [cited]; CC BY-SA 3.0 (http://creativecommons.org/licenses/by-sa/3.0). Available from: https://commons.wikimedia.org/wiki/File%3AComparison_semiconductor_process_nodes.svg
   Google Scholar
• Au P, Hursh DA, Lim A, et al. FDA oversight of cell therapy clinical trials. Sci Transl Med. 2012;4(149):149fs31.
   PubMed Web of Science ®Google Scholar
• Arjmand B, Aghayan HR. Cell manufacturing for clinical applications. Stem Cells. 2014;32(9):2557–2558.
   PubMed Web of Science ®Google Scholar
• Lysaght MJ. Product development in tissue engineering. Tissue Eng. 1995;1(2):221–228.
   PubMedGoogle Scholar
• Martin I, Smith T, Wendt D. Bioreactor-based roadmap for the translation of tissue engineering strategies into clinical products. Trends Biotechnol. 2009 9;27(9):495–502. DOI:10.1016/j.tibtech.2009.06.002
   PubMed Web of Science ®Google Scholar
• Hambor JE. Bioreactor design and bioprocess controls for industrialized cell processing. BioProcess Int. 2012;10(6):22–33.
   Google Scholar
• Timmins NE, Athanasas S, Günther M, et al. Ultra-high-yield manufacture of red blood cells from hematopoietic stem cells. Tissue Eng Part C Methods. 2011;17(11):1131–1137.
   PubMed Web of Science ®Google Scholar
• Mason C, Dunnill P. Assessing the value of autologous and allogeneic cells for regenerative medicine. Regen Med. 2009;4(6):835–853.
   PubMed Web of Science ®Google Scholar
• Muschler GF, Nakamoto C, Griffith LG. Engineering principles of clinical cell-based tissue engineering. J Bone Joint Surg Am. 2004;86(7):1541–1558.
   PubMed Web of Science ®Google Scholar
• Lipsitz YY, Timmins NE, Zandstra PW. Quality cell therapy manufacturing by design. Nat Biotechnol. 2016;34(4):393–400.
   PubMed Web of Science ®Google Scholar
• Prestwich GD, Bhatia S, Breuer CK, et al. What is the greatest regulatory challenge in the translation of biomaterials to the clinic? Sci Transl Med. 2012;4(160):160cm14–160cm14. DOI:10.1126/scitranslmed.3004915
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Eder R, Kunz-Schughart LA, et al. Large-scale in vitro expansion of polyclonal human CD4+ CD25high regulatory T cells. Blood. 2004;104(3):895–903.
   PubMed Web of Science ®Google Scholar
• Wang X, Riviere I. Manufacture of tumor-and virus-specific T lymphocytes for adoptive cell therapies. Cancer Gene Ther. 2015;22(2):85–94.
   PubMed Web of Science ®Google Scholar
• Pangarkar N, Hutmacher DW. Invention and business performance in the tissue-engineering industry. Tissue Eng. 2003;9(6):1313–1322.
   PubMedGoogle Scholar
• Hollister SJ. Scaffold engineering: a bridge to where? Biofabrication. 2009;1(1):012001–012001. PubMed PMID: 20811095 . DOI:10.1088/1758-5082/1/1/012001
   PubMed Web of Science ®Google Scholar
• Lysaght MJ, Nguy NA, Sullivan K. An economic survey of the emerging tissue engineering industry. Tissue Eng. 1998;4(3):231–238.
   PubMedGoogle Scholar
• Ducheyne P, Healy K, Hutmacher DE, et al. Comprehensive Biomaterials II. Elsevier Science. 2017.
   Google Scholar
• Mason C, Manzotti E. The translation cycle: round and round in cycles is the only way forward for regenerative medicine. Regen Med. 2010;5(2):153–155.
   PubMed Web of Science ®Google Scholar
• Mason C, Dunnill P. Lessons for the nascent regenerative medicine industry from the biotech sector. Regen Med. 2007;2(5):753–756. 2007/09/01. DOI:10.2217/17460751.2.5.753
   PubMed Web of Science ®Google Scholar
• Tang Q, Lee K. Regulatory T-cell therapy for transplantation: how many cells do we need? Curr Opin Organ Transplant. 2012;17(4):349–354.
   PubMed Web of Science ®Google Scholar
• Mason C, Dunnill P. The need for a regen industry voice. Regen Med. 2008;3(5):621–631. 2008/09/01. DOI:10.2217/17460751.3.5.621
   PubMed Web of Science ®Google Scholar
• Chhaya MP, Poh PSP, Balmayor ER, et al. Additive manufacturing in biomedical sciences and the need for definitions and norms. Expert Rev Med Devices. 2015;12(5):537–543. PubMed PMID: 36690903.
   PubMed Web of Science ®Google Scholar
• Blanchard BS, Blyler JE. Introduction to system engineering. System engineering management. Hoboken, NJ, USA: John Wiley & Sons, Inc; 2016. p. 1–52.
   Google Scholar
• Estefan JA. Survey of model-based systems engineering (MBSE) methodologies. Incose MBSE Focus Group. 2007;25(8):1–70.
   Google Scholar
• Blanchard BS, Blyler JE. The system engineering process. System engineering management. Hoboken, NJ, USA: John Wiley & Sons, Inc; 2016. p. 53–124.
   Google Scholar
• Blyler J. Interface management. IEEE Instrum Meas Mag. 2004;7(1):32–37.
   Web of Science ®Google Scholar
• Hollister SJ. Hierarchical bioactive materials for tissue reconstruction: integrated design and manufacturing challenges [journal article]. Jom. 2011;63(4):56–65.
   Web of Science ®Google Scholar
• Langer R. Editorial: tissue engineering: perspectives, challenges, and future directions. Tissue Eng. 2007;13(1):1–2.
   PubMedGoogle Scholar
• Mason C. Regenerative Medicine 2.0. Regen Med. 2007;2(1):11–18. PubMed PMID: 870532064; 17465770 . DOI:10.2217/17460751.2.1.11
   PubMed Web of Science ®Google Scholar
• Dori D, Choder M. Conceptual modeling in systems biology fosters empirical findings: the mRNA lifecycle. PLoS One. 2007;2(9):e872.
   PubMed Web of Science ®Google Scholar
• Chikofsky EJ, Cross JH. Reverse engineering and design recovery: a taxonomy. IEEE Software. 1990;7(1):13–17.
   Web of Science ®Google Scholar
• Hollister SJ, Murphy WL. Scaffold translation: barriers between concept and clinic. Tissue Eng B: Rev. 2011;17(6):459–474.
   PubMed Web of Science ®Google Scholar
• Brown TD, Dalton PD, Hutmacher DW. Direct writing by way of melt electrospinning. Advanced Mater. 2011;23(47):5651–5657.
   PubMed Web of Science ®Google Scholar
• Lutolf MP, Hubbell JA. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering [10.1038/nbt1055]. Nat Biotech. 2005;23(1): 47–55. 01//print.
   PubMed Web of Science ®Google Scholar
• Holzapfel BM, Reichert JC, Schantz J-T, et al. How smart do biomaterials need to be? A translational science and clinical point of view. Adv Drug Deliv Rev. 2013;65(4):581–603. 4//. DOI:10.1016/j.addr.2012.07.009
   PubMed Web of Science ®Google Scholar
• Delalat B, Harding F, Gundsambuu B, et al. 3D printed lattices as an activation and expansion platform for T cell therapy. Biomaterials. 2017 9;140:58–68. DOI:10.1016/j.biomaterials.2017.05.009
   PubMed Web of Science ®Google Scholar
• Lindgren K, Salmén A, Lundgren M, et al. Automation of cell line development. Cytotechnology. 2009;59(1):1–10. PubMed PMID: PMC2677144. DOI:10.1007/s10616-009-9187-y
   PubMed Web of Science ®Google Scholar
• Nerem RM. Cell-based therapies: from basic biology to replacement, repair, and regeneration. Biomaterials. 2007;28(34):5074–5077. 2007/12/01. DOI:10.1016/j.biomaterials.2007.07.032
   PubMed Web of Science ®Google Scholar
• Bluestone JA, Trotta E, Xu D. The therapeutic potential of regulatory T cells for the treatment of autoimmune disease. Expert Opin Ther Targets. 2015;19(8):1091–1103. 2015/08/03. DOI:10.1517/14728222.2015.1037282
   PubMed Web of Science ®Google Scholar
• Themeli M, Rivière I, Sadelain M. New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell. 2015;16(4):357–366.
   PubMed Web of Science ®Google Scholar
• Poirot L, Philip B, Schiffer-Mannioui C, et al. Multiplex genome-edited T-cell manufacturing platform for “off-the-shelf” adoptive T-cell immunotherapies. Cancer Res. 2015;75(18):3853–3864.
   PubMed Web of Science ®Google Scholar
• Bas O, De-Juan-Pardo EM, Meinert C, et al. Biofabricated soft network composites for cartilage tissue engineering. Biofabrication. 2017;9(2):025014.
   PubMed Web of Science ®Google Scholar
• Bas O, De-Juan-Pardo EM, Chhaya MP, et al. Enhancing structural integrity of hydrogels by using highly organised melt electrospun fibre constructs. Eur Polym J. 2015;72:451–463.
   Web of Science ®Google Scholar
• Youssef A, Hollister SJ, Dalton PD. Additive manufacturing of polymer melts for implantable medical devices and scaffolds. Biofabrication. 2017;9(1):012002.
   PubMed Web of Science ®Google Scholar
• Roseti L, Serra M, Bassi A. Standard operating procedure for the good manufacturing practice-compliant production of human bone marrow mesenchymal stem cells. In: Turksen, Kursad, Editors. Stem Cells and Good Manufacturing Practices: Methods, Protocols, and Regulations. 2015. pp. 171–186.
   Google Scholar
• Papantoniou I, Chai YC, Luyten FP, et al. Process quality engineering for bioreactor-driven manufacturing of tissue-engineered constructs for bone regeneration. Tissue Eng Part C Methods. 2013;19(8):596–609.
   PubMed Web of Science ®Google Scholar
• Bilek M, Kosobrodova E, Wakelin EA, et al. Cost-effective creation of biofunctionalised scaffolds, tailored to function as stem cell niches for expansion, transport and delivery. Cytotherapy. 2016;18(6,Number 6 Supplement 1):S60–S60. PubMed PMID: 38642589.
   Web of Science ®Google Scholar
• Ho ST, Hutmacher DW. A comparison of micro CT with other techniques used in the characterization of scaffolds. Biomaterials. 2006 3;27(8):1362–1376. DOI:10.1016/j.biomaterials.2005.08.035
   PubMed Web of Science ®Google Scholar
• Henkel J, Schantz JT, Hutmacher DW. Computer aided design of scaffolds for bone tissue engineering. Osteologie. 2013;22(3):180–187. PubMed PMID: 31372577.
   Web of Science ®Google Scholar
• Olsen TR, Lock LT, Rowley JA. Scaling up: how manufacturing sciences will dictate the future of cell therapy. FUTURE MEDICINE LTD UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND; 2016.
   Google Scholar
• Mason C, Dunnill P. The crucial linkage required between regenerative medicine bioprocessors and clinicians. Regen Med. 2008;3(4):435–442. 2008/07/01. DOI:10.2217/17460751.3.4.435
   PubMed Web of Science ®Google Scholar
• Mason C, Dunnill P. Quantities of cells used for regenerative medicine and some implications for clinicians and bioprocessors. Regen Med. 2009;4(2):153–157.
   PubMed Web of Science ®Google Scholar
• Bilek M, Kosobrodova E, Wakelin EA, et al. 103 - Cost-effective creation of biofunctionalised scaffolds, tailored to function as stem cell niches for expansion, transport and delivery. Cytotherapy. 2016 6;18(6):S60. DOI:10.1016/j.jcyt.2016.03.124
   Web of Science ®Google Scholar
• Kirouac DC, Zandstra PW. The systematic production of cells for cell therapies. Cell Stem Cell. 2008;3(4):369–381. 10/9/. DOI:10.1016/j.stem.2008.09.001
   PubMed Web of Science ®Google Scholar
• Hollister SJ. Scaffold design and manufacturing: from concept to clinic. Advanced Mater. 2009;21(32‐33):3330–3342.
   PubMed Web of Science ®Google Scholar
• Woodruff MA, Lange C, Reichert J, et al. Bone tissue engineering: from bench to bedside. Mater Today. 2012 10;15(10):430–435. DOI:10.1016/S1369-7021(12)70194-3
   Web of Science ®Google Scholar